Luteolin protects T2DM animals against diabetic cardiomyopathy by suppressing the c-JUN N-terminal kinase (JNK)-suppressed autophagy pathway [31] and improves vascular complications associated with T2DM by improving the systemic and metabolic profile in T2DM Goto-Kakizaki rats [32]. Here, MAPK8 is linked to diabetic cardiomyopathy.